Reinsurance Group of America Posts Record EPS, Resets Mix
Reinsurance Group Of America ((RGA)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Reinsurance Group of America Earnings Call Shows Strong Momentum Despite Health Exit
Reinsurance Group of America’s latest earnings call struck a confident and largely upbeat tone, underscored by record earnings, double‑digit book value growth, and return on equity above target. Management highlighted robust regional performance, substantial gains in the value of in‑force business, and disciplined capital deployment, including resumed share buybacks. While the quarter included some headwinds—most notably unfavorable biometric claims and a strategic exit from the U.S. group health business—the overall narrative emphasized balance sheet strength, earnings quality, and a clear roadmap for sustainable growth, even as executives cautioned that in‑force transaction timing and investment income recognition could introduce some near‑term variability.
Record Quarterly and Full-Year Earnings
RGA delivered another standout quarter, posting Q4 operating EPS of $7.75, marking the second consecutive record quarter and capping a year of record operating earnings for 2025. Management framed these results as evidence that the company’s diversified global franchise and in‑force management strategy are translating into consistent bottom‑line performance. Investors focused on the EPS trajectory will see this as a strong foundation for the newly articulated run‑rate EPS level and the company’s multi‑year growth targets.
Return on Equity Above Target Range
Adjusted operating ROE over the trailing 12 months, excluding notable items, reached 15.7%, above RGA’s intermediate‑term target range of 13%–15%. Management emphasized that this elevated ROE is not solely a function of transient items but underpinned by recurring business and disciplined capital deployment. Sustained ROE above the upper end of the target band supports the investment case that RGA can generate attractive returns while maintaining prudent risk management.
Value of In-Force Business Rises Sharply
One of the most striking data points from the call was the $6.6 billion, or 18%, increase in the value of in‑force business in 2025. Over the past two years, that value has increased by more than $11 billion, implying roughly 16% annual growth. Management underscored that in‑force optimization, re‑pricing, and capital‑efficient transactions have become core earnings drivers, enlarging the pool of predictable cash flows that support long‑term profitability and capital return.
Regional Engines Drive Earnings Power
RGA’s geographic diversification continued to pay off, with particularly strong contributions from APAC and EMEA. APAC pretax operating income (excluding notable items) rose 18% for the year, while EMEA pretax earnings jumped 35%. North America also benefited from the Equitable block acquisition and in‑force actions that added incremental earnings. Together, these regions demonstrated that growth is broad‑based rather than dependent on a single market, reducing concentration risk and enhancing earnings stability.
Capital Deployment and Balance Sheet Strength
The company leaned heavily into its capital deployment strategy in 2025, investing $2.5 billion into in‑force transactions while still ending Q4 with an estimated $2.7 billion of excess capital and approximately $3.4 billion of deployable capital over the next 12 months. Management portrayed this as evidence of both balance sheet robustness and an ongoing pipeline of attractive risk‑adjusted opportunities. The firm’s ability to simultaneously grow earnings, expand in‑force value, and retain substantial excess capital is central to its equity story.
Reinstated Share Buybacks and Evolving Capital Return Mix
RGA has resumed returning more capital directly to shareholders, repurchasing $50 million of stock in Q4 and $125 million since buybacks were reinstated. The company aims for a total payout ratio—dividends plus buybacks—of 20%–30% of after‑tax operating earnings over the intermediate term. Management stressed that repurchases will be opportunistic and balanced against in‑force transaction opportunities and leverage reduction, signaling a flexible approach to optimizing shareholder value.
Premium Growth Shows Underlying Business Momentum
Traditional premium growth reached 7.4% year‑to‑date on a constant currency basis, reflecting healthy demand across North America, EMEA, and APAC. This premium expansion indicates that RGA is not solely reliant on in‑force transactions for growth; it is also winning new business and expanding existing relationships. For investors, steady premium growth provides a key indicator of the franchise’s competitive positioning and future earnings capacity.
Investment Performance and Variable Income Tailwinds
Investment results provided an extra boost in Q4, with variable investment income running about $48 million above expectations. This upside was driven by higher limited partnership income and the repositioning of acquired portfolios to more attractive return profiles. While management cautioned that such upside is inherently volatile, the quarter showcased how RGA’s investment platform can enhance earnings in favorable environments.
In-Force Management Actions Continue to Add Value
In‑force management actions were again a meaningful contributor, with favorable impacts of approximately $75 million in 2023, $225 million in 2024, and about $135 million in 2025. In Q4 alone, such actions added around $95 million. These initiatives—ranging from re‑pricing to structural changes in existing blocks—have become a repeatable source of value creation, providing levers for RGA to enhance profitability without relying exclusively on new business volumes.
Book Value Growth Underpins Long-Term Value Creation
Book value per share, excluding AOCI and certain embedded derivative impacts, climbed to $165.50, translating into a 10% compounded annual growth rate since 2021. Management highlighted this metric as a key indicator of long‑term shareholder value creation, reflecting the combined impact of retained earnings, in‑force value accretion, and disciplined capital allocation. For equity holders, the steady compounding in book value adds confidence that reported earnings are being translated into tangible net worth.
Unfavorable Biometric Claims Pressure Q4 Results
Not everything broke in RGA’s favor in the quarter. Economic claims experience was unfavorable by $51 million in Q4, translating into a $53 million negative current‑period financial impact, with roughly half tied to U.S. group business. Management framed these results as a discrete headwind within an otherwise favorable longer‑term claims trend, noting that since 2023 economic claims have still been net positive. Nonetheless, the quarter served as a reminder of the inherent claims volatility in protection businesses.
Strategic Exit from U.S. Group Health Business
The most significant strategic shift announced was the decision to stop writing and not renew U.S. excess medical/group health business after a period of underperformance. This portfolio—around $400 million of annual premium generating roughly $25 million of pretax run‑rate earnings—had experienced unacceptably high volatility and disappointing results, prompting full repricing with average rate hikes of about 40% effective mid‑2025 through early 2026 and then a full exit. Management framed the move as a disciplined capital reallocation away from low‑return, high‑volatility lines toward more attractive opportunities in its core life and health reinsurance segments.
Reduced Predictability of In-Force Actions
RGA cautioned that the timing and size of future in‑force management actions will be highly unpredictable, and that 2026 is likely to see more limited financial contributions from such actions than in recent years. Given the sizable earnings boosts these actions have provided, particularly in 2024 and 2025, this shift introduces additional uncertainty into near‑term earnings patterns. Management emphasized that underlying business growth and capital deployment should offset much of this variability over time, but investors should expect less frequent large one‑off benefits.
Corporate and Other Losses Remain a Structural Drag
Corporate and Other posted an adjusted operating loss before tax of $54 million in Q4, and the company expects this bucket to remain in the roughly $50–$55 million loss range per quarter in 2026. These losses are driven by higher financing costs and general corporate expenses. While not a surprise, this segment remains a structural drag on consolidated results, and management’s guidance effectively sets expectations that any improvement here will be gradual rather than sudden.
Real Estate-Linked Investment Income and Assumptions
RGA set its 2026 variable investment income assumption at 7%, slightly higher than 2025’s 6% but below its long‑term expectation of 10%–12%. The conservative stance reflects a muted environment for real estate sales, where much of the income recognition on alternative assets occurs. Management’s discussion underscored that while long‑run returns from these investments remain attractive, near‑term income recognition will be constrained by subdued transaction volumes, contributing to some earnings variability.
Dependence on Ongoing Deployment and Execution
The company’s intermediate‑term EPS growth guidance of 8%–10% relies on the assumption that it can consistently deploy around $1.5 billion annually into in‑force transactions and continue to execute well on both new and existing business. Additional capital deployment, as well as the timing and ramp‑up of new deals, introduces year‑to‑year uncertainty in reported results. Management argued that the overall trajectory remains firmly positive, but investors will need to monitor deal flow, pricing discipline, and integration performance as key drivers of whether RGA meets or exceeds its targets.
Guidance and Forward-Looking Outlook
Looking ahead, RGA set a 2025 run‑rate adjusted operating EPS of about $24.75 per share and reaffirmed its intermediate‑term targets of 8%–10% annual EPS growth and a 13%–15% ROE, anchored by the current 15.7% trailing 12‑month adjusted operating ROE. The company’s 2026 planning assumptions include variable investment income of 7%, a tax rate of 22%–23%, and run‑rate Corporate & Other losses of approximately $50 million–$55 million per quarter. Capital priorities for 2026 center on deploying roughly $1.5 billion into in‑force transactions, allocating around $400 million toward reducing financial leverage, and executing opportunistic share buybacks within a 20%–30% total payout framework, backed by $2.7 billion of excess capital and roughly $3.4 billion of deployable capital over the next 12 months. Additional factors baked into the outlook include the expectation that in‑force actions will contribute less than in prior years, Equitable transaction earnings stepping up to $160 million–$170 million in 2026, and the retrocession vehicle being fully deployed by mid‑2026.
RGA’s earnings call painted a picture of a company in strong financial health, leveraging its global footprint and in‑force expertise to deliver record earnings and robust ROE, while prudently returning capital to shareholders. The decision to exit U.S. group health and the caution around future in‑force actions and investment income reflect a sober assessment of risk and volatility rather than a shift in the overall growth story. For investors, the key takeaways are a solid balance sheet, clear capital allocation priorities, and a credible path to mid‑single‑digit to low‑double‑digit earnings growth—albeit with some near‑term noise as the business mix evolves and capital continues to be deployed.
